Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Vijay Pande, founding partner of a16z bio and health strategy, steps down

From TechCrunch

By Marina Temkin

June 10, 2025

Vijay Pande, founding partner of a16z bio and health strategy, steps down

Vijay Pande, founding partner of a16z bio and health strategy, steps down

Vijay Pande, a general partner at Andreessen Horowitz who founded the firm’s a16z Bio + Health strategy, announced that he is stepping down from his role.

Since its founding in 2014, a16z Bio + Health has raised four funds, including a $1.5 billion fund that closed in 2022. However, it’s now seeking a much smaller $750 million fifth fund, The Wall Street Journal reported. In January, a16z Bio + Health announced that it will separately manage a $500 million biotech fund funded by pharmaceutical giant Eli Lilly.

a16z Bio + Health backs digital health startups and companies at the intersection of AI, computation, and biology.

Pande’s investments include Devoted Health, an individualized medical plan provider; Function Health, a personalized lab testing startup; and Freenome, a company aiming to detect cancer through blood draws. Before joining Andreessen Horowitz, Pande was a professor of chemistry, structural biology, and computer science at Stanford University.

The remaining partners on the a16z Bio + Health team are Jorge Conde, Julie Yoo, and Vineeta Agarwala.

View original article on techcrunch.com

Most Recent

AI-powered travel agency Fora hits unicorn status, raises $60M

AI-powered travel agency Fora hits unicorn status, raises $60M

Travel agency Fora announced a $60 million Series D round led by Forerunner and Tactile Ventures, valuing the company at $1 billion.

Jul 16, 2026

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.

Jul 14, 2026

DeepSeek reportedly in talks to raise $1.5B, then IPO

DeepSeek reportedly in talks to raise $1.5B, then IPO

DeepSeek, the Chinese large language model developer, is said to be preparing for a 2027 IPO debut as it also looks to raise around $1.5 billion in new funds at a $71 billion valuation.

Jul 14, 2026

Similar Posts

Obvious Ventures lands fund five with a 360-degree view of planetary, human, economic health

Obvious Ventures lands fund five with a 360-degree view of planetary, human, economic health

The 12-year-old firm raised $360,360,360 for its fifth fund. And there's a reason for that number.

Jan 26, 2026

a16z pauses its famed TxO Fund for underserved founders, lays off staff

a16z pauses its famed TxO Fund for underserved founders, lays off staff

Andreessen Horowitz is pausing its Talent x Opportunity (TxO) fund and program, according to multiple sources.

Nov 3, 2025

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners closed its second fund, raising $82 million. It hopes to invest in at least 25 early-stage companies, writing check sizes between $1 million and $2.3 million, with 50% of the fund reserved for follow-on investments.

May 29, 2025

Andreessen Horowitz denies report of India office, calls it ‘fake news’

Andreessen Horowitz denies report of India office, calls it ‘fake news’

a16z’s Anish Acharya calls India office reports “entirely fake news!”

Oct 9, 2025

Most Recent

AI-powered travel agency Fora hits unicorn status, raises $60M

AI-powered travel agency Fora hits unicorn status, raises $60M

Travel agency Fora announced a $60 million Series D round led by Forerunner and Tactile Ventures, valuing the company at $1 billion.

Jul 16, 2026

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.

Jul 14, 2026

DeepSeek reportedly in talks to raise $1.5B, then IPO

DeepSeek reportedly in talks to raise $1.5B, then IPO

DeepSeek, the Chinese large language model developer, is said to be preparing for a 2027 IPO debut as it also looks to raise around $1.5 billion in new funds at a $71 billion valuation.

Jul 14, 2026

Similar Posts

Obvious Ventures lands fund five with a 360-degree view of planetary, human, economic health

Obvious Ventures lands fund five with a 360-degree view of planetary, human, economic health

The 12-year-old firm raised $360,360,360 for its fifth fund. And there's a reason for that number.

Jan 26, 2026

a16z pauses its famed TxO Fund for underserved founders, lays off staff

a16z pauses its famed TxO Fund for underserved founders, lays off staff

Andreessen Horowitz is pausing its Talent x Opportunity (TxO) fund and program, according to multiple sources.

Nov 3, 2025

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners announces close of $82M Fund II

Zeal Capital Partners closed its second fund, raising $82 million. It hopes to invest in at least 25 early-stage companies, writing check sizes between $1 million and $2.3 million, with 50% of the fund reserved for follow-on investments.

May 29, 2025

Andreessen Horowitz denies report of India office, calls it ‘fake news’

Andreessen Horowitz denies report of India office, calls it ‘fake news’

a16z’s Anish Acharya calls India office reports “entirely fake news!”

Oct 9, 2025